IgA Nephropathy

Rizk discusses the recent FDA accelerated approval of iptacopan (Fabhalta) and reflects on the significance of other therapeutic developments in IgAN.

The majority of highly suspected COVID-19 vaccine-associated glomerular disease cases were diagnosed as immunoglobulin A nephropathy and eventually improved with treatment.

Results suggest the potential utility of several nutritional indexes for reflecting IgAN severity and predicting end-stage renal disease risk.

Findings from the bidirectional 2-sample Mendelian randomization study suggest a strong positive causal association between atopic dermatitis and IgAN.

Findings suggest increased intensity of IgM deposits in patients with positive IgM deposition may contribute to adverse clinicopathologic presentation and clinical outcomes.

The updated pediatric IgAN prediction tool allows clinicians to assess risk of disease progression 1-2 years post-biopsy.

Findings from a prespecified secondary analysis of the reduced-dose cohort of the TESTING trial suggest the efficacy of a lower dose of oral methylprednisolone in IgA nephropathy.

On August 07, 2024, Novartis announced the FDA's accelerated approval of iptacopan for reducing proteinuria in primary IgAN based on interim data from APPLAUSE-IgAN.

Study findings suggest the need for individualized management of patients with IgAN following COVID-19 infection based on baseline renal function status.

Findings support the use of mineralocorticoid receptor antagonists for the short-term reduction of proteinuria in patients with IgAN.

This July 2024 month in review highlights renal pipeline updates, new patient-focused CKD guidelines, and other top nephrology news and research.

The high diagnostic and prognostic application values of newer IgAN machine learning models suggest their eventual utility in clinical practice.

Findings suggest greater CTSS levels are associated with an elevated risk of IgAN and highlight the enzyme’s potential as a diagnostic biomarker.

Gross hematuria due to infection was not associated with the incidence of gross hematuria due to vaccination in patients with IgAN who received COVID-19 mRNA vaccination.

Patients with chronic tonsillitis had greater IgAN event rates than those without, and further analysis revealed chronic tonsillitis was linked to a greater risk of developing IgAN.

Findings highlight the prognostic value of metabolic syndrome components in predicting both renal and cardiovascular outcomes in patients with IgA nephropathy.

This June 2024 month in review spotlights HCPLive’s coverage of the latest renal news and research in IgA nephropathy, differences in care, and novel associations in nephrology.

A Mendelian randomization analysis found co-localization between the target genes of SGLT2 inhibitors and the pathogenesis genes of membranous nephropathy and IgAN.

Findings suggest machine learning models may have promising utility in IgAN, highlighting the superior diagnostic performance of certain models versus standard logistic regression.

Lower free thyroxine levels were linked to worse renal outcomes in patients with IgAN, and free thyroxine with tubular atrophy/interstitial fibrosis had high predictive value for IgAN prognosis.

Survey results called attention to gaps in physicians’ clinical knowledge of IgAN, with incorrect responses prevalent among both specialists and generalists.

Data collected from parallel online surveys revealed notable differences in IgA nephropathy treatment among patients and nephrologists from the US, EU5, Japan, and China.

A post-hoc analysis of the phase 2b ORIGIN study highlights atacicept’s impact on hematuria, with more patients achieving improvement and resolution at 36 weeks than those on placebo.

In our nephrology month in review for May 2024, we spotlight the biggest news from the NKF and ERA meetings, including the latest updates in IgA nephropathy, C3 glomerulopathy, chronic kidney disease, and more!

Results suggest certain peroxiredoxins may be viable prognostic markers in glomerulopathies, including IgA nephropathy and membranous nephropathy.